NCT07525635EARLY_PHASE1Recruiting
Aspirin Dosing in Pregnancy
NYU Langone Health
Start Date
4/27/2026
Completion Date
2/20/2028
Summary
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Eligibility Criteria
Age Range: 18 years to 50 years
Inclusion Criteria:
* Pregnant people prior to 17 weeks
* Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
* Age 18-50 years
* Singleton viable gestation
* Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.
Exclusion Criteria:
* Undergoing glucose challenge test (GCT) at time of blood draw
* Allergy or intolerance to aspirin
* Antithrombotic or antiplatelet therapy
* Anemia (hemoglobin \<10 g/dl) or thrombocytopenia (platelet count \<100,000), or thrombocytosis (platelet count \>600,000)
* Known hemorrhagic diathesis
* Planned delivery outside of NYU
Interventions
DRUG
Aspirin
Conditions
Preeclampsia Possible
Locations
NYU Langone Health
New York, New York 10016
United States